Diagnosis and management of cholangiocarcinoma

Current Gastroenterology Reports

Volumn 10, Issue 1, 2008, Pages 43-52

  Sandhu, Dalbir S ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CHOLAGOGUE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; IRINOTECAN; MITOMYCIN; MONOCLONAL ANTIBODY; NVP AEE788; OXALIPLATIN; PORPHYRIN; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VASCULOTROPIN INHIBITOR;

BILE DUCT CARCINOMA; BILIARY TRACT ENDOSCOPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CHEMOEMBOLIZATION; CHOLANGIOGRAPHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE MODEL; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; GENETIC STABILITY; HUMAN; LIVER TRANSPLANTATION; MOLECULAR THERAPY; MONOTHERAPY; MORBIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SEROLOGY; SIGNAL TRANSDUCTION; STENT; SYMPTOM; BILE DUCT TUMOR; INTRAHEPATIC BILE DUCT;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS;

EID: 51549121090     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0008-9     Document Type: Review

References (62)

1. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24: 115-125.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996, 46: 5-27.
3. Ahrendt SA, Pitt HA: Biliary tract. In Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 16th edn. Edited by Townsend CM, Jr. Philadelphia: W. B. Saunders Co.; 2001:1076-1111.
4. Nagorney DM, Donohue JH, Farnell MB, et al.: Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993, 128: 871-877, discussion 877-879.
5. Fevery J, Verslype C, Lai G, et al.: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007, 52: 3123-3135.
6. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 1999, 10(Suppl 4): 308-311.
7. Roskams T: Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006, 25: 3818-3822.
8. Sirica AE: ChoMangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41: 5-15.
9. Henson DE, Albores-Saavedra J, Corle D: Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992, 70: 1498-1501.
10. de Groen PC, Gores GJ, LaRusso NF, et al.: Biliary tract cancers. N Engl J Med 1999, 34: 1368-1378.
11. Khan SA, Davidson BR, Goldin R, et al.: Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002, 51(Suppl 6): VI1-9.
12. Bloom CM, Langer B, Wilson SR: Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics 1999, 19: 1199-1218.
13. Rösch T, Meining A, Frühmorgen S, et al.: A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 2002, 55: 870-876.
14. Itoh S, Ikeda M, Ota T, et al.: Assessment of the pancreatic and intrapancreatic bile ducts using 0.5-mm collimation and multiplanar reformatted images in multislice CT. Eur Radiol 2003, 13: 277-285.
15. Tillich M, Mischinger HJ, Preisegger KH, et al.: Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998, 171: 651-658.
16. Cha JH, Han JK, Kim TK, et al.: Preoperative evaluation of Klatskin tumor: Accuracy of spiral CT in determining vascular invasion as a sign of unresectability. Abdom Imaging 2000, 25: 500-507.
17. Braga HJ, Imam K, Bluemke DA: MR imaging of intrahepatic cholangiocarcinoma: Use of ferumoxides for lesion localization and extension. AJR Am J Roentgenol 2001, 177: 111-114.
18. Yeh TS, Jan YY, Tseng JH, et al.: Malignant perihilar biliary obstruction: Magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 2000, 95: 432-440.
19. Lee SS, Kim MH, Lee SK, et al.: MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc 2002, 56: 25-32.
20. Lopera JE, Soto JA, Munera F: Malignant hilar and perihilar biliary obstruction: Use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001, 220: 90-96.
21. Kuszyk BS, Soyer P, Bluemke DA, Fishman EK: Intrahepatic cholangiocarcinoma: The role of imaging in detection and staging. Crit Rev Diagn Imaging 1997, 38: 59-88.
22. Bain VG, Abraham N, Jhangri GS, et al.: Prospective study of biliary strictures to determine the predictors of malignancy. Can J Gastroenterol 2000, 14: 397-402.
23. Rösch T, Hofrichter K, Frimberger E, et al.: ERCP or EUS for tissue diagnosis of biliary strictures? A prospective comparative study. Gastrointest Endosc 2004, 60: 390-396.
24. Levy MJ, Vazquez-Sequeiros E, Wiersema MJ: Evaluation of the pancreaticobiliary ductal systems by intraductal US. Gastrointest Endosc 2002, 55: 397-408.
25. Wakabayashi H, Akamoto S, Yachida S, et al.: Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol 2005, 31: 1175-1179.
26. Kluge R, Schmidt F, Caca K, et al.: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001, 33: 1029-1035.
27. Kim YJ, Yun M, Lee WJ, et al.: Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003, 30: 1467-1472.
28. Poneros JM, Tearney GJ, Shiskov M, et al.: Optical coherence tomography of the biliary tree during ERCP. Gastrointest Endosc 2002, 55: 84-88.
29. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al.: Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999, 31: 305-309.
30. Kipp BR, Stadheim LM, Halling SA, et al.: A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004, 99: 1675-1681.
31. Baron TH, Harewood GC, Rumalla A, et al.: A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004, 2: 214-219.
32. Moreno Luna LE, Kipp B, Halling KC, et al.: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131: 1064-1072.
33. Nichols JC, Gores GJ, LaRusso NF, et al.: Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993, 68: 874-879.
34. Ramage JK, Donaghy A, Farrant JM, et al.: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995, 108: 865-869.
35. Bjornsson E, Kilander A, Olsson R: CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999, 19: 501-508.
36. Nehls O, Gregor M, Klump B: Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004, 24: 139-154.
37. Wu T, Han C, Lunz JG III, et al.: Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 2002, 36: 363-373.
38. Itoi T, Shinohara Y, Takeda K, et al.: Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers. Int J Mol Med 2001, 7: 281-287.
39. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000, 60: 184-190.
40. Kim BH, Cho NY, Choi M, et al.: Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch Pathol Lab Med 2007, 131: 923-930.
41. D'Angelica MI, Jarnagin WR, Blumgart LH: Resectable hilar cholangiocarcinoma: Surgical treatment and long-term outcome. Surg Today 2004, 34: 885-890.
42. Seyama Y, Makuuchi M: Current surgical treatment for bile duct cancer. World J Gastroenterol 2007, 13: 1505-1515.
43. Di Stefano DR, de Baere T, Denys A, et al.: Preoperative percutaneous portal vein embolization: Evaluation of adverse events in 188 patients. Radiology 2005, 234: 625-630.
44. Rea DJ, Heimbach JK, Rosen CB, et al.: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242: 451-458, discussion 458-461.
45. Flamm CR, Mark DH, Aronson N: Evidence-based assessment of ERCP approaches to managing pancreaticobiliary malignancies. Gastrointest Endosc 2002, 56(Suppl): S218-S225.
46. Baer HU, Rhyner M, Stain SC, et al.: The effect of communication between the right and left liver on the outcome of surgical drainage for jaundice due to malignant obstruction at the hilus of the liver. HPB Surg 1994, 8: 27-31.
47. De Palma GD, Galloro G, Siciliano S, et al.: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: Results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001, 53: 547-553.
48. Ishii H, Furuse J, Nagase M, et al.: Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: Results without stenting. Hepatogastroenterology 2004, 51: 954-957.
49. Hong YS, Lee J, Lee SC, et al.: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007, 60: 321-328.
50. Kim ST, Park JO, Lee J, et al.: A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006, 106: 1339-1346.
51. Bhargava P, Jani CR, Savarese DM, et al.: Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: Preliminary report. Oncology (Williston Park) 2003, 17(Suppl 8): 23-26.
52. Ortner ME, Caca K, Berr F, et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: A randomized prospective study. Gastroenterology 2003, 125: 1355-1363.
53. Berr F: Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 2004, 24: 177-187.
54. Rumalla A, Baron TH, Wang KK, et al.: Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001, 53: 500-504.
55. Jakus J, Farkas O: PhotosensiAizers and antioxidants: a way to new drugs? Photochem Photobiol Sci 2005, 4: 694-698.
56. Burger I, Hong K, Schulick R, et al.: Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Interv Radiol 2005, 16: 353-361.
57. Prat F, Lafon C, De Lima DM, et al.: Endoscopic treatment of cholangiocarcinoma and carcinoma of the duodenal papilla by intraductal high-intensity US: Results of a pilot study. Gastrointest Endosc 2002, 56: 909-915.
58. Wiedmann M, Feisthammel J, Blüthner T, et al.: Novel targeted approaches to treating biliary tract cancer: The dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006, 17: 783-795.
59. TrAxler P, Allegrini PR, Brandt R, et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004, 64: 4931-4941.
60. Higuchi R, Yamamoto M, Hatori T, et al.: Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: Report of a case. Surg Today 2006, 36: 559-562.
61. Hayashi H, Asano R, Tsumoto K, et al.: A highly effective and stable bispecific diabody for cancer immunotherapy: Cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 2004, 53: 497-509.
62. Takemura S, Kudo T, Asano R, et al.: A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother 2002, 51: 33-44.